Quick Answer
Arcus Biosciences, Inc. reported Earnings Per Share Diluted of $3.29 (loss) per share for the year ending 2025.
- Arcus Biosciences, Inc. showed a decrease of -4.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Arcus Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $1.09 (loss) per share | Q2 2023: $1.04 (loss) per share | Q3 2023: $0.94 (loss) per share | Q1 2024: $0.05 (loss) per share | Q2 2024: $1.02 (loss) per share | Q3 2024: $1.00 (loss) per share | Q1 2025: $1.14 (loss) per share | Q2 2025: $0.00 per share | Q3 2025: $1.27 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Arcus Biosciences, Inc.'s Earnings Per Share Diluted has grown by 11.3%.
- Historical annual values: Fiscal year 2025: $3.29 (loss) per share | Fiscal year 2024: $3.14 (loss) per share | Fiscal year 2023: $4.15 (loss) per share | Fiscal year 2022: $3.71 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: